



Prothena Corporation plc
 Investor Relations Department
 331 Oyster Point Blvd
 South San Francisco, CA 94080
 United States

[Visit IR website](#)
[Sign-up for Email alerts](#)


NASDAQ: PRTA	
Last Trade:	14.62
Trade Time:	4:00 PM ET May 25, 2018
Change:	-0.24 (-1.615%)
Day Range	14.48 - 15.15
52-Week Range	10.43 - 70.00
Volume	403,893

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Prothena Corporation plc (Nasdaq: PRTA) is a global, late-stage clinical biotechnology company establishing fully integrated research, development and commercial capabilities and focused on advancing new therapies in the neuroscience and orphan categories. Fueled by a deep scientific understanding built over decades of research in protein misfolding, we seek to fundamentally change the course of grave or currently untreatable diseases associated with this biology. Our pipeline of antibody therapeutic candidates targets a number of indications including AL amyloidosis (NEOD001), Parkinson... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 24, 2018*
[Prothena Announces Reorganization to Focus Resources on Advancing Neuroscience Pipeline](#)
- May 8, 2018*
[Prothena Reports First Quarter 2018 Financial Results and Provides R&D Update](#)
- May 1, 2018*
[Prothena to Report First Quarter 2018 Financial Results on May 8](#)
- Apr 23, 2018*
[Prothena Discontinues Development of NEOD001 for AL Amyloidosis](#)
- Mar 20, 2018*
[Prothena Announces Global Neuroscience Research & Development Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative Diseases](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Feb 26, 2018*
[Annual Report \(10-K\)](#)
- Mar 29, 2018*
[Proxy Statement \(DEF 14A\)](#)
- May 9, 2018*
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2017*
[Quarterly Report \(10-Q\)](#)